Retinoblastoma (RB) is the most common primary intraocular cancer in children, and the third most common cancer overall in infants. No molecular-targeted therapy for this lethal tumor exists. Since the tumor suppressor RB1, whose genetic inactivation underlies RB, is upstream of the epigenetic regulator EZH2, a pharmacologic target for many solid tumors, we reasoned that EZH2 might regulate human RB tumorigenesis. Histologic and immunohistochemical analyses were performed using an EZH2 antibody in sections from 43 samples of primary, formalin-fixed, paraffin-embedded human RB tissue, cryopreserved mouse retina, and in whole cell lysates from human RB cell lines (Y79 and WERI-Rb1), primary human fetal retinal pigment epithelium (RPE) and fetal and adult retina, mouse retina and embryonic stem (ES) cells. Although enriched during fetal human retinal development, EZH2 protein was not present in the normal postnatal retina. However, EZH2 was detected in all 43 analyzed human RB specimens, indicating that EZH2 is a fetal protein expressed in postnatal human RB. EZH2 expression marked single RB cell invasion into the optic nerve, a site of invasion whose involvement may influence the decision for systemic chemotherapy. To assess the role of EZH2 in RB cell survival, human RB and primary RPE cells were treated with two EZH2 inhibitors (EZH2i), GSK126 and SAH-EZH2 (SAH). EZH2i impaired intracellular adenosine triphosphate (ATP) production, an indicator of cell viability, in a time and dose-dependent manner, but did not affect primary human fetal RPE. Thus, aberrant expression of a histone methyltransferase protein is a feature of human RB. This is the first time this mechanism has been implicated for an eye, adnexal, or orbital tumor. The specificity of EZH2i toward human RB cells, but not RPE, warrants further in vivo testing in animal models of RB, especially those EZH2i currently in clinical trials for solid tumors and lymphoma.
rate of children with RB in the United States is over 90%, 4 the tumor is lethal in 50-70% of children in non-developed countries. 5, 6 Even among survivors, RB treatments are associated with significant co-morbidities, including retinopathy, secondary cancers, neutropenia and other local and systemic toxicities. [7] [8] [9] [10] [11] Aside from changes in RB1 and MYCN, few other somatic genetic aberrations have been identified, 12 limiting the development of novel, rationally designed therapeutics. One relatively new avenue for rational drug development in cancer involves post-translational modification of chromatin, termed epigenetics. Epigenetic agents can alter how tightly histones bind DNA, which, in turn, determines the accessibility of the DNA to transcriptional machinery. 13, 14 Thus, modulation of histones can change expression of oncogenes or tumor suppressors in cancers, even without the introduction of DNA mutations. [14] [15] [16] [17] In this work, we propose that the histone methyltransferase (HMT), EZH2/Ezh2 (human/mouse), an enzyme that catalyzes trimethylation at lysine 27 on histone H3 (H3K27me3), is selectively expressed in RB tumors, required for tumor survival, and thus represents a novel therapeutic target. 17 EZH2, which is expressed in several highly proliferative, aggressive tumors, 18 triggers transcriptional silencing of tumor suppressors such as the cyclin-dependent kinase inhibitor p16/INK4a and p19/Arf. [19] [20] [21] EZH2's oncogenic actions are suppressed by RB1 and related protein P130, 22, 23 and retinoblastoma formation in mice requires the joint inactivation of both RB1 and P130. 24 SUZ12 mRNA, which encodes a protein that is a co-factor for EZH2, is upregulated in human RB, further implicating EZH2 in RB oncogenesis. 25 Accordingly, herein we explore the clinical application of labeling retinoblastoma with EZH2 to aid in the detection of invasive RB cells. Currently histopathologic detection of single invasive RB cells to adjacent tissues remains difficult, even though invasion to the optic nerve is an indication for systemic chemotherapy following enucleation. Finally, our work raises the possibility that pharmacologic targeting of EZH2, the basis of two ongoing oncology clinical trials, 26 may be a promising strategy toward the development of the first molecularly targeted therapies for RB.
MATERIALS AND METHODS Immunofluorescence Microscopy
Mouse retinal tissue sections and human retinoblastoma cell cultures were fixed in 4% paraformaldehyde and processed as previously described. 27, 28 For immunofluorescence labeling, retinal tissue sections or retinoblastoma cell cultures blocked with 5% bovine serum albumin+5% normal goat serum +0.3% triton X-100 in PBS for 1 h at room temperature. The blocking buffer was discarded, and the sections were washed three times with 1 × PBS, before the addition of antibodies Ezh2 (1:200, Cell Signaling, Beverly, MA, USA #5246, rabbit monoclonal D2C9 clone) and CRX (1:500, Abnova, Taipei, Taiwan, H00001406-M02, mouse monoclonal M02 clone). Incubation was performed overnight at 4°C. Sections were washed three times, followed by incubation with secondary antibodies (1:200, Abcam, Cambridge, MA, USA ab150074 donkey anti-rabbit polyclonal Alexa Fluor 555; ab150105 donkey anti-mouse polyclonal Alexa Fluor 488; ab150073 donkey anti-rabbit polyclonal Alexa Fluor 488) conjugated with a fluorophore for 1 h in the dark. The sections were washed again three times with 1 × PBS for 30 min After staining with 4′,6-diamidino-2-phenylindole (DAPI, 2 mg/ml, Sigma, St Louis, MO, USA) to reveal cell nuclei, retinal sections were mounted and examined under fluorescence and confocal laser scanning microscopy (SP5; Leica, Wetzlar, Germany).
Fetal Retina Samples and Cell Culture of Primary Fetal RPE and Human RB Cell Lines Human retinoblastoma cell lines WERI-Rb1 (HTB-169) and Y79 (HTB-18) were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in RPMI-1640 media (ATCC, #30-2001) supplemented with fetal calf serum (10% for WERI-Rb1 and 20% for Y79). Human fetal retina was obtained from eyes at 19 weeks gestational age (Advanced Bioscience Resources, Alameda, CA, USA), shipped on ice in RPMI media, and dissected within 26 h post mortem. The protocol of Maminishkis et al 29 was followed with the following modifications. After anterior segment removal, the eyecup was incubated in complete RPE media with 5% heat-inactivated fetal bovine serum (Life Technologies, Brown Deer, WI, USA; #10082-147) and dispase (Worthington Biochem., Lakewood, NJ, USA; LS02109) at 4.5 U/ml for 90 min at 37°C in a 5% CO 2 incubator. After incubation, the retina naturally separated from the underlying RPE, and was freed from the optic nerve with scissors. Retina was used for western blotting and immunohistochemistry. The eyecup was then inverted and placed on a plastic dome created by cutting the bottom off of a microcentrifuge tube. The inverted eyecup and plastic dome were pinned to a dissecting dish filled with silicone elastomer. RPE collected from one fetal eye was plated on one 25 cm 2 Primaria flask (Corning, Corning, NY, USA; 08-772-45). After 4-10 weeks, cells were split using trypsin again according to the protocol of Maminishkis et al, although some patches of tightly adherent RPE required a second trypsin incubation for up to an hour. Trypsinized cells were plated on 24-well transwells coated with human placental extracellular matrix (BD Biosciences, San Jose, CA, USA) at a splitting density of 1:1.5, with each transwell estimated to have a surface area of 0.3 cm 2 . Cells were grown on Transwells for 4-8 weeks before testing with EZH2 inhibitors. EZH2 peptide and small molecule inhibitors SAH-EZH2 (#508320) and GSK126 (#15415) were purchased from Millipore (Billerica, MA, USA) and Cayman Chemical (Ann Arbor, MI, USA), respectively.
Collection and Clinicopathologic Analysis of Primary Human Retinoblastoma Tissues
After approval by the University of Michigan Institutional Review Board, we retrospectively searched the electronic pathology archives for all cases of enucleation for retinoblastoma without prior treatment, diagnosed between January 1988 and June 2014. Fifty-seven cases of enucleation for untreated retinoblastoma in 57 children during the study period were identified. Formalin-fixed paraffin-embedded (FFPE) blocks were available for 43 out of 57 cases. Clinical data collected included age at the time of enucleation (in months), gender and laterality at the time of presentation. FFPE tissue blocks were cut in five-micrometer-thick sections and stained with hematoxylin and eosin. Slides were reviewed and histologic features recorded. The largest dimension of tumor in centimeters was determined by a combination of slide evaluation and review of the gross description. Histologic grade was determined by the estimated percentage of Flexner-Wintersteiner rosettes (1 = well differentiated, 2 = moderately differentiated, 3 = poorly differentiated and 4 = undifferentiated). Well-differentiated tumors demonstrated rosettes in 480% of fields examined, while poorly differentiated tumors contained rare rosettes or showed Homer-Wright rosettes. Moderately differentiated tumors were in between these two grades. Undifferentiated tumors showed no rosettes. The extent of optic nerve invasion and choroidal invasion was evaluated according to the guidelines presented in the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 7th edition. Briefly, the extent of optic nerve invasion was recorded as 1 = no invasion, 2 = anterior to lamina cribrosa, 3 = at lamina cribrosa and 4 = posterior to lamina cribrosa, while choroidal invasion was recorded as 0 = no invasion, 1 = focal invasion and 2 = massive invasion (at least 0.3 cm).
Immunohistochemistry
Immunohistochemical staining was performed on the DAKO Autostainer (DAKO, Carpinteria, CA, USA) using DAKO Envision+ and diaminobenzadine as the chromogen. Sections of de-paraffinized human fetal week 19 retina or postnatal retinoblastoma sections were labeled with EZH2 (mouse monoclonal antibody, clone 11, 1:100, BD Biosciences, San Jose, CA, USA; #612666) for 60 min at ambient temperature. Microwave epitope retrieval in 10 mM Tris/HCl, pH 9 containing 1 mM EDTA was used before staining. Appropriate negative (no primary antibody) and positive controls (reactive tonsil) were stained in parallel with each set of tumors studied. EZH2 immunostains were examined by light microscopy by two pathologists (LLW and APS). Only EZH2 staining of the nucleus was marked as positive EZH2 expression. The staining was scored semiquantitatively and recorded based on percent nuclei staining (0 = negative, 1 = 1-25% immunoreactive cells, 2 = 26-50% immunoreactive cells, 3 = 51-75% immunoreactive cells and 4 = 76-100% immunoreactive cells) and intensity of staining (0 = negative, 1 = weak, 2 = moderate, 3 = strong). Corresponding sections were also labeled with hematoxylin and eosin, as previously described. 12, 30, 31 Cell Viability Assay Cell viability was assessed using CellTiter-Glo Luminescent Cell Viability Kit (Promega, Madison, WI, USA; #G7570) by measurement of intracellular adenosine triphosphate (ATP). Briefly, two retinoblastoma cell lines (5 × 10 4 cells per well in a 24-well plate) were treated with different doses of EZH2 inhibitors (SAH-EZH2 twice daily, GSK 126 daily). After 48 h, 80 μl of cell suspensions were harvested and mixed with 20 μl of CellTiter-Glo lysis buffer in a 96-well assay plate (Costar, Corning, Tewksbury, MA, USA; #3912). After 10 min of incubation following manufacturer's instructions, luminescence was recorded using a SpectraMax M5 plate reader. For primary RPE, cells were cultured in 24-transwell inserts with 125 μl of media per well and treated with EZH2 inhibitors for 48 h. After removing 75 μl of cell culture media, 50 μl of CellTiter-Glo lysis buffer was added to each transwell. 100 μl of cell lysate was transferred to a 96-well assay plate and incubated at room temperature for 10 min. Luminescence was then recorded using a Veritas TM microplate luminometer (Turner Biosystems, Sunnyvale, CA, USA; #9100-102).
Western Blot Analysis
Cells treated with different doses of EZH2i at indicated time points were harvested and cell lysates were prepared using mPER mammalian protein extraction reagent (ThermoScientific, Waltham, MA, USA; #78503). An amount of 20 μg of total protein was loaded per lane, run on a 12% SDS-polyacrylamide gel electrophoresis gel and further transferred to PVDF membrane (Millipore, IPFL00010). The EZH2 antibody was obtained from Cell Signaling (clone D2C9), and ß-actin (Cell Signaling, #4967S) was used to probe for equal loading.
Histone Analysis
Histone extraction was performed using a kit according to manufacturer's protocol (Abcam, catalog #: ab113476). Histone concentration was measured by BCA method, and 1 μg of histone was loaded on SDS-PAGE gel for western blot. The following antibodies were used: H3K27me3 (Millipore, #07-449), H3K4me3 (Millipore, #07-473) and total histone H3 (Abcam, #ab1791).
Statistical Analysis
The Χ 2 -test was used to determine statistical significance of categorical variables and analysis of variance was used to analyze continuous variables. Associations among EZH2 staining percentage/intensity and clinicopathologic features were determined by Pearson's correlation analysis. All statistical analyses were run using GraphPad Prism version 6.01 for Windows, GraphPad Software, La Jolla CA, USA, www.graphpad.com. A P-value o0.05 was considered statistically significant.
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RESULTS

EZH2 Expression During Retinal Development
To determine the developmental expression of EZH2 in the mammalian retina, we extended our previous results 28 by western blotting for Ezh2 in the mouse retina at various developmental timepoints and used mouse embryonic stem (ES) cells as a control. At its peak at embryonic days 15-17 (E15-17), Ezh2 protein levels were higher than at the ES cell stage. Levels in adult retina were nearly undetectable ( Figure 1a) . Immunofluorescence of Ezh2 levels at E17 vs adult mouse retina confirmed these findings (Figure 1b) . Similar results were seen during human retinal development: retinal lysates from fetal week 19 (fw19) contained higher levels of EZH2 than the adult retina ( Figure 2a ). To confirm these results and to localize the protein in normal human retinal development, we performed immunohistochemistry in human fw19 retina, and found EZH2 to be expressed mainly in the outer neuroblastic layer, a known proliferative region of the fetal human retina (Figure 2c and e). We did not detect EZH2 in non-RB tumor infiltrated, normal postnatal human retina ( Figure 3f ). These results indicate the EZH2 is a fetal protein normally expressed during mouse and human retinal development.
EZH2 Expression in Human RB Cell Lines
Since many cancers aberrantly express fetal proteins in postnatal tissues, and because RB1 inhibits EZH2, 22, 23 we suspected human RB cells obtained from the postnatal eye would express EZH2. We used western blotting to compare EZH2 protein levels from two human RB cell lines, WERIRb1 and Y79, 32, 33 with primary human fetal RPE cultures and human retina from fw19 and adult. EZH2 levels were significantly higher in WERI-Rb1 and Y79 RB cells than in fw19 and adult human retina (Figure 2a ) or primary human fetal RPE cultures (Figure 2b) . The cell-of-origin for human RB has been suggested to be a CRX-positive, cone photoreceptor precursor. 30, 31 Immunofluorescence confirmed that WERI-Rb1 cells express CRX and EZH2 (Figure 2f ). These results demonstrate that EZH2 expression, normally transiently present during development, is expressed in human RB cells.
EZH2 Expression in Human RB Enucleation Samples
In vitro cancer cell lines, such as WERI-Rb1 and Y79, do not recapitulate some aspects of primary malignancies, and we considered the possibility that increased EZH2 protein in RB cell lines might not reflect EZH2 levels in primary human RB samples. To directly examine EZH2 protein levels in primary tumors, we performed a retrospective search of the electronic pathology archives, which yielded 43 cases of RB for which FFPE blocks were available. The mean age at enucleation was 21 months for all cases; 8 months for well-differentiated tumors, 17 months for moderately differentiated tumors, 30 months for poorly differentiated tumors and 33 months for undifferentiated tumors. All cases had negative optic nerve margins. The clinicopathologic features of these samples are summarized in Table 1 .
Following specimen collection, we probed for the presence of EZH2 protein by immunohistochemistry using human RB tumor sections from the 43 enucleations. All cases demonstrated nuclear EZH2 expression within tumor cells, with varying degrees of intensity (Supplementary Figure) and Figure 1 Ezh2 expression in the mouse retina. (a) Western blot of whole retina isolated from the indicated ages showed that Ezh2 protein levels from whole retina peaked during mid-gestation and decreased during postnatal and adult stages. β-actin was used as a loading control. (b) Immunofluorescence of frozen mouse retinal sections at indicated ages confirmed that Ezh2 protein (green) was more abundant in the retina during E17 than in the adult. DAPI, 4′,6-diamidino-2-phenylindole; E, embryonic day; GCL, ganglion cell layer; INL, inner nuclear layer; NBL, neuroblastic layer; ONL, outer nuclear layer; P, postnatal day. (Table 2) . We identified a positive correlation between percentage and intensity of EZH2 staining (Po0.001), but did not find any correlations between EZH2 and other clinicopathologic features (Supplementary Table) . Other clinicopathologic correlations for non-EZH2 variables were found and are detailed in the Supplementary Material.
The presence of EZH2 protein delineated the entire extent of the intraocular tumor (Figure 3a and b, black arrowheads) as well as extraocular components, such as optic nerve invasion (Figure 3a and b, white arrowheads) . EZH2 was present in tumor cells that formed characteristic RB histopathologic structures such as Homer Wright and FlexnerWintersteiner rosettes (Figure 3c and d) . The generally strong nuclear staining of RB tumor cells against the negative background provided an unprecedented histopathologic resolution that allowed detection of both bulk tumor (Figure 3e and f, black arrowheads) as well as single RB cell (g and h) . GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; IS/OS, photoreceptor inner/outer segments; ON, optic nerve; ONL, outer nuclear layer; OPL, outer plexiform layer; RPE, retinal pigment epithelium.
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M Khan et al invasion into adjacent tissues, such as the inner plexiform layer (Figure 3e and f, white arrowheads) and optic nerve (Figure 3g and h, white arrowheads), and choroid (data not shown). EZH2 protein was not detected in non-tumor cells, including intact neural retina and RPE (Figure 3e and f). These data indicate that EZH2 is specifically expressed in primary human RB tumors, and that the presence of EZH2 resolves single-cell, metastatic RB cell invasion into adjacent structures. Although EZH2 expression appeared specific for RB cells, it did not mark all tumor cells. In three specimens, there were areas of EZH2-positive and negative RB cells (Figure 4a and b, black and white arrowheads, respectively). Interestingly, RB tumor cells that exhibited photoreceptor differentiation were negative for EZH2 (Figure 4a, inset, b) . Two other specimens had unusual EZH2 staining patterns that were more likely related to specimen preparation. One tumor demonstrated loss of EZH2 staining in areas where tumor was not well preserved. The second tumor showed a loss of EZH2 staining only posteriorly, but this pattern did not correlate with specific histologic features. Taken together, these findings demonstrate that the presence of EZH2 protein specifically discriminates RB cells from normal tissue. Furthermore, differentiation state appeared to correlate with EZH2 expression, as foci of RB cells exhibiting photoreceptor differentiation were EZH2-negative.
Selectivity of EZH2 Inhibitors toward Human RB Cells
Since we found that EZH2 protein was selectively enriched in human RB cell lines and primary tumors, but not in nontumor cells, we hypothesized that pharmacologic EZH2 inhibition might preferentially target primary RB cells but spare non-tumor cells of embryologic retinal origin, such as RPE.
To test this possibility, we administered two recently developed EZH2 inhibitors (EZHi), the small molecule GSK126 and the peptide SAH-EZH2 (SAH), to WERI-Rb1, Y79, and primary human fetal RPE cells. GSK126 inhibits the enzymatic SET domain of EZH2, while SAH blocks interaction of EZH2 with its essential co-factor EED, an interaction which is required for Polycomb Repressive Complex 2 (PRC2)-mediated gene repression activity. 34 , 35 We used (Figure 5a and d) . At 48 h, we found that GSK126 concentrations of 7.5 μM or greater was sufficient to decrease EZH2 protein levels in Y79 and WERI-Rb1 cells (Figure 5a and c) . Similar concentrations of SAH did not affect EZH2 protein levels in WERI-Rb1 and Y79 cells (Figure 5b and d) .
We considered the possibility that GSK126 and SAH may inhibit EZH2 activity without affecting its protein level. 35, 36 To test this, we assessed levels of H3K27me3, a substrate for EZH2, with and without inhibitor treatment. We found that H3K27me3 levels, but not H3K4me3 levels (negative control), decreased in Weri-Rb1 and Y79 at GSK126 concentrations of 2.5 μM and higher (Figure 5e ). In contrast, we did not find a change in H3K27me3 levels at SAH concentrations ranging from 2.5 to 10 μM (Figure 5f ). These data indicate that GSK126 inhibits EZH2 enzymatic activity at H3K27me3 at doses that do not change EZH2 protein levels in human RB cell lines (o 7.5 μM), consistent with previous reports on other human tumor cell lines. 35 Based on the experiments above, we used a similar doseresponse scheme to treat WERI-Rb1 and Y79 with EZH2i for 48 h in an MTT assay. Both inhibitors decreased ATP content, an indicator of cell viability, in RB cells at concentrations above 5 μM, suggesting that EZH2 is required for viability in human RB cells ( Figure 6 ). We reasoned that since primary human fetal RPE-which share a similar embryologic origin as RB-expressed much less EZH2 than RB cells (Figure 2b, d and e), they would be less sensitive to EZH2i. Indeed, we saw no change in viability of primary human fetal RPE even at 25 μM of SAH or GSK126, a level of EZH2i that greatly reduced viability in WERI-Rb1 cells (Figure 6c) . From these data, we conclude that differential EZH2 protein levels predict response to EZH2i, and that EZH2i selectively impairs RB cell viability.
DISCUSSION
The discovery of the gene responsible for retinoblastoma, RB1, introduced the concept of a tumor suppressor to the field of cancer biology. 37 Further, Knudson's investigation of RB inheritance led to the 'two-hit' hypothesis of cancer: a mechanism by which loss of heterozygosity (LOH) of a second allele subsequent to a germline mutation in the first allele leads to cancer. 38 Interestingly, functional LOH can be caused not only by mutation within a second RB1 allele but also functional silencing of a normal, non-mutant RB1 copy by allele-specific DNA hypermethylation. 39 This mechanism, epigenetic silencing by allele-specific DNA methylation, rather than mutation, also introduced a novel concept to cancer biology. Thus, the study of RB has contributed to key advances in the understanding of the genetic and epigenetic underpinnings of cancer overall.
Despite a 30-year understanding of RB, no rationally targeted therapies based on the unique biology of RB exist. Currently, chemotherapy and enucleation form the backbone of RB therapy. 8 Although these therapies are effective in the US, the rate of treatment-related secondary cancers remains high, and in non-developed countries where therapeutic options are limited, RB mortality rates can reach 70%. 5,6,8 A In this study, we identify the HMT EZH2 protein as the first epigenetic enzyme to be dysregulated in human RB. Specifically, we found EZH2 was abundant in cultured human RB cell lines and RB tumor samples, but absent in nonproliferating cells of the normal fetal and postnatal retina. In fact, in eyes enucleated for advanced RB, EZH2 protein could be used as a marker to identify single RB cells invading into adjacent tissues such as the optic nerve. EZH2's specific presence in RB tissue suggested the protein might be a therapeutic target. Indeed, we found that inhibitors of EZH2 killed human RB cells, but not primary human RPE cultures. Our findings raise the possibility that EZH2i may underpin a novel strategy against human RB, the first based on exploiting a targetable epigenetic enzyme specifically enriched in human RB.
In this work, we also extended our previous findings in the mouse retina 28 to show, for the first time, that EZH2 is expressed transiently during human retinal development but completely repressed postnatally in non-tumorigenic retina. Indeed, EZH2 has been shown to be important for multiple developmental processes, as Ezh2 knockout mouse embryos die before completing gastrulation. 40 EZH2's dual role in development and cancer is well-demonstrated in the lung, where it is present during early lung development, downregulated by late gestation, and re-expressed in subtypes of lung carcinoma. 41, 42 Thus, previous work is consistent with our finding that EZH2 is an oncoprotein that has a normally transient, developmentally specific function.
Interestingly, we found that while EZH2 appears to be a specific marker for RB, it does not mark all RB cells. We noted that EZH2 protein is low or absent in focal regions of RB tumor that displayed enhanced photoreceptor differentiation. These areas do not have a high rate of cellular turnover and necrosis and therefore tend to persist in older patients. 43 The three patients in this study showing foci of photoreceptor differentiation with absence of EZH2 staining had poorly or moderately differentiated tumors and were 20, 21 and 26 months of age. In a prior study, Eagle et al 44 evaluated photoreceptor differentiation in a cohort of enucleated eyes with retinoblastoma and found that photoreceptor differentiation was identified in tumors of all histologic grades and that the mean age of patients was 23 months. The absence of EZH2 staining in the foci of photoreceptor differentiation is not surprising given photoreceptor differentiation is hypothesized to be a remnant of the precursor lesion (retinocytoma) rather than re-differentiation of the retinoblastoma. 45, 46 In our clinicopathologic analysis, EZH2 protein was not correlated with histologic grade. Nevertheless, a larger study of RB tumors may be consistent with the possibility that EZH2 may correlate to degree of cellular differentiation, as noted during retinal development and in other carcinomas. 18 To this end, it would be interesting to assess EZH2 expression in a precursor RB variant, retinocytoma (retinoma), which we predict would have lower EZH2 expression than RB. Nevertheless, we remain uncertain of the significance EZH2 +/high and EZH2 − /low RB cell populations, and whether EZH2i may be more effective at eliminating EZH2+/high vs EZH2 − /low RB cells.
Although we identified EZH2 protein in all RB enucleation samples, and that the proportion of EZH2 positivity correlated with staining intensity, we did not find a relationship between EZH2-related features and a variety of clinicopathologic features including age, laterality, tumor size, and optic nerve/choroidal invasion. A limitation of this study was that we were unable to analyze the relationship among EZH2 EZH2 in human retinoblastoma M Khan et al variables, tumor recurrence, and patient survival because the full clinical histories for many patients were not available. Nevertheless, we suspect that increased presence of EZH2 protein in RB tumors correlates with recurrence and poor prognosis, as it does in a variety of other cancers. 18 A future study with more complete patient records, and possibly a larger number of patients, would be helpful to verify this hypothesis.
Lei et al 47 recently demonstrated that EZH2 mRNA levels, measured by quantitative real-time polymerase chain reaction (qRT-PCR), are significantly upregulated in RB. Furthermore, they found that EZH2 transcripts are specifically higher in tumors with high-risk features such as poor differentiation, choroidal invasion, and orbital invasion. However, our study showed no association between EZH2 protein levels and histologic grade or high-risk invasive features. One explanation is that the upregulation of mRNA does not result in the sustained accumulation of EZH2 protein, due to posttranslational modifications. 48, 49 Another explanation may be the sensitivity of qRT-PCR vs immunohistochemistry in quantifying EZH2 levels.
A limitation of the Lei et al 47 study was the inability to localize EZH2 protein to specific cell types, as RNA was prepared from whole tissue extracts. In contrast, our immunohistochemical studies allowed localization of EZH2 protein specifically to the proliferating parts of fetal retina and postnatal RB cells. Our analysis allowed us to detect RB invasion into adjacent tissues, which has clinical implications. For instance, pathologic evaluation of the tumor margin at the optic nerve and analysis of distal optic nerve for the presence of RB cells may influence therapeutic decisionmaking. Specifically, positive tumor margins or RB invasion toward distal segments of the optic nerve may lead to a decision to use systemic chemotherapy. We found that EZH2 staining may be helpful as a histopathologic tool because this protein can resolve both the bulk and single tumor cells invading adjacent tissues, which may be otherwise difficult to detect with standard hematoxylin & eosinstaining. However, only a minority of our cases displayed optic nerve invasion, and none had a positive margin. Also, since RB foci with fleurette photoreceptor differentiation were not stained with EZH2, EZH2 may not be sufficiently sensitive to detect all RB cells invading into the optic nerve. Therefore, a study involving invasive RB with positive margins containing fleurette components would be helpful in determining whether EZH2 would be helpful as a marker for metastatic invasion.
Intravitreal and intraophthalmic artery chemotherapy are emerging as globe-preserving therapies for advanced RB, for which affected eyes may otherwise undergo primary enucleation. However, one common agent, mephalan, has been reported to be toxic to the retina and choroid, 9, 11 and may also cause systemic effects, such as neutropenia. 10 Intravitreal and intraophthalmic artery approaches could be strengthened by delivery of agents that are more specific to the tumor while sparing non-involved tissues. Our preliminary data with EZH2i indicates that the high EZH2 expression specifically in RB tumor cells, but not primary human RPE, can be pharmacologically exploited. Indeed, a recent microarray profiling study of advanced human RB tumors has revealed EZH2 to be among the most downregulated genes in regressed tumors following systemic chemotherapy. 50 Future studies should address local and systemic delivery and toxicities of EZH2i in animal models of RB.
Human RB has among the lowest mutational rates reported in cancer to date. 12 The stable genome of RB limits the effectiveness of therapies that depend on targeting accumulated passenger mutations. Nearly all RB tumors are (e-f) Western blot of histone methylation status in whole cell lysates of WERI-Rb1 and Y79 following incubation with (e) indicated concentrations of GSK126 for 48 h or indicated periods of treatment at 5 μM of GSK126 or (f) indicated concentrations of SAH-EZH2 for 48 h. H3K27Me3 represents the histone methylation target of EZH2, whereas H3K4Me3 represents a site unaffected by the enzyme (negative control). H3 represents total histone 3 protein levels, which should also be unaffected by EZH2 modulation.
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M Khan et al characterized by biallelic inactivation of RB1, but carry few other mutations. Despite this genetic homogeneity, the behavior of individual RB tumors remains diverse, likely due to epigenetic variations. Thus, epigenetic regulators should be integrated into any approach toward novel RB therapeutics. 12 Our goal was to identify a candidate epigenetic regulator whose dysregulation was not only common to RB and other solid tumors but was also a rapidly actionable target. EZH2 fits both these categories, and our group had the benefit of being the first to identify this protein in the mammalian retina. 28 In this report, we reasoned that since EZH2 is expressed solely in RB tumor cells, but not in any other postnatal retinal cell type, RB tumor would be susceptible to EZH2 inhibition. Indeed, we identify two EZH2i, GSK126, and SAH-EZH2, as potential therapeutic candidates that selectively impair RB cell viability but spare non-tumor retinal cells. Yet, the precise mechanism by which these EZH2i acts on human RB cells may vary. At 5 μM, GSK126 did not affect EZH2 protein levels, but reduced H3K27me3 and viability in RB cells. This is consistent with the mechanism of action of GSK126 as a SET domain inhibitor that selectively reduces EZH2 enzymatic activity at its substrate, H3K27me3, before any effects on EZH2 protein level. 35 In contrast, across a range of concentrations, SAH-EZH2 did not change EZH2 protein levels or H3K27me3 status, but did selectively inhibit RB cell viability at 12.5 μM or higher without impairing fetal primary RPE viability. Inhibition of H3K27me3-independent EZH2 pathways has emerged as a potentially therapeutic target in castration-resistant prostate cancer and other advanced solid tumors. 36 Given that SAH-EZH2 inhibits EZH2 activity by disrupting its interaction with EED, an essential co-factor, rather than directly blocking EZH2's enzymatic pocket, a H3K27me3-independent mechanism may account for SAH-EZH2's effects on RB cells in our assays. Thus, our report highlights two pharmacologic probes that can be used to interrogate H3K27me3-dependent and independent pathways in cancers that require EZH2 for survival.
EZH2i for cancer is a rapidly advancing field marked by deep commitments from a variety of biopharmaceutical companies. 48, 51 Three clinical trials, NCT01897571, NCT02082977, and NCT02395601 (clinicaltrials.gov), are currently recruiting patients with subsets of B-cell lymphoma, pediatric malignant rhabdoid tumor (MRT), synovial sarcoma, and other advanced solid tumors for treatment with small molecule EZH2i. These agents, EPZ-6438 (E7438) and GSK2816126, inhibit the enzymatic domain of EZH2 and are most closely related to GSK126 used in this study. In the case of B-cell lymphoma, patients may carry wild type or a gain-of-function EZH2 mutant allele; the latter has not been reported in human RB to date. 3, 12 In contrast, MRT and synovial sarcoma are pediatric solid tumors that, like RB, do not carry an EZH2 mutation, but carry another mutation (SMARCB1, also known as INI1, hSNF5, and BAF47) that sensitizes the cancer to EZH2i. 52, 53 Our work raises the possibility that if approved, these or newer generation EZH2i could be repurposed for evaluation in animal models of RB, and if promising, potentially toward human RB therapy. Finally, we suspect EZH2 dysregulation to be a common feature among various types of ophthalmic, adnexal, and orbital tumors. Thus EZH2i may offer a launching point toward the development of the first generation of rationally designed, epigenetic therapies for ocular oncology.
Supplementary Information accompanies the paper on the Laboratory Investigation website (http://www.laboratoryinvestigation.org)
